Rucaparib is a PARP inhibitor that is being studied for the treatment of mCRPC. Rucaparib has not been approved by any regulatory body, including the FDA, for the treatment of patients with prostate cancer. Rucaparib is thought to work by targeting key proteins (PARP) involved in the DNA repair process. Cancer cells undergo rapid DNA replication, therefore, mistakes in their DNA sequence can quickly accumulate if they are not repaired, leading to tumor cell death. Rucaparib is being studied to evaluate its effect in men with mCRPC with alterations in the breast cancer (BRCA) and ataxia telangiectasia mutated (ATM) genes. Other genetic markers that are being studied to determine if they can identify men who may respond to rucaparib include BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, and RAD54L.
Such alterations in DNA-repair genes can be detected with tests that physicians can perform on DNA from prostate cancer cells.
ABOUT AVAILABLE TRITON TRIALS.
You may be eligible to participate in a TRITON clinical trial if:
You are at least 18 years of age
Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
For TRITON3, patients must not have previously been treated with a taxane therapy for mCRPC
Have experienced disease progression after treatment with at least 1 prior next generation androgen receptor-targeted therapy (abiraterone acetate, enzalutamide) for mCRPC
Have a deleterious alteration in BRCA1/2 or ATM
Enrollment into the TRITON2 trial is now closed